R egeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects ...

Veru Inc. VERU recently announced the selection of a novel modified-release oral formulation for enobosarm for chronic weight loss management. Enobosarm is a selective androgen receptor modulator ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Plus more pharma news from the Pharmalittle newsletter.

But the drug still achieved significant weight loss over 48 weeks, raising hopes about its potential over a longer period of time. Meanwhile, Novo Nordisk's weekly injection Wegovy only targets GLP-1.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Men's Health Weight loss drugs like Ozempic can raise low testosterone — what that means for men By Tracy Swartz Published July 14, 2025, 3:00 p.m. ET ...